scispace - formally typeset
J

Jeffrey M. Peters

Researcher at Pennsylvania State University

Publications -  217
Citations -  21665

Jeffrey M. Peters is an academic researcher from Pennsylvania State University. The author has contributed to research in topics: Peroxisome proliferator-activated receptor & Receptor. The author has an hindex of 74, co-authored 214 publications receiving 20405 citations. Previous affiliations of Jeffrey M. Peters include Lawrence Livermore National Laboratory & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice.

TL;DR: Evidence is provided that metabolism of phenacetin by CYP1A2 alters toxicity in vivo, and suggests that alternate CYP 1A2-independent metabolic pathways contribute to its toxicity.
Journal ArticleDOI

Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)

TL;DR: Results from these studies demonstrate that inhibition of COX2 by dietary sulindac in mouse skin can effectively inhibit chemically induced skin carcinogenesis, and suggest that the mechanism underlying this chemopreventive effect is independent of PPARbeta.
Journal ArticleDOI

PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer

TL;DR: It is postulate that activation of the nuclear receptor PPARdelta by COX-2-derived prostanoids may be involved in the proliferation of mammary epithelial cells and therefore contribute to mammary cancer development.
Journal Article

Comparative effects of essential and nonessential metals on preimplantation mouse embryo development

TL;DR: In this paper, the influence of four essential (Cu, Mn, Fe, Zn), and eight nonessential (Cr, Hg, Pb, V, Al, Ag, Cd, As) metals on mouse preimplantation embryonic development was investigated.
Journal ArticleDOI

Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ).

TL;DR: This review summarizes both the confirmed and conflicting mechanisms that have been described for PPARβ/δ and the potential for targeting this nuclear receptor for the prevention and treatment of colon cancer.